Fig. 4: Proof-of-concept study in a large animal model of post-MI HF.
From: Preclinical development of a miR-132 inhibitor for heart failure treatment
a Study outline of treatment regimen (LAD = left anterior descending coronary artery). b Ejection fraction (EF) at baseline, day 3 and day 56 for different dosing groups of intracoronary/intravenous (ICIV) and intravenous/intravenous (IVIV) treated animals (Placebo: NaCl; Low = 1 mg/kg, Medium = 5 mg/kg and High = 10 mg/kg antimiR-132). c Functional improvement indicated by EF change from day 3 to day 56 (delta EF) for different dosing groups of ICIV and IVIV treated animals. d Responder analysis for different dosing groups of ICIV and IVIV treated animals. e N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels at baseline and day 56 for different dosing groups of ICIV and IVIV treated animals. f Quantification and representative micrographs of picrosirius red (PSR) staining of the left ventricular (LV) remote regions for different dosing groups of ICIV and IVIV treated animals (scale bar = 200 µm). g Quantification and representative micrographs of wheat germ agglutinin (WGA) staining for cardiac cell size measurement of the LV remote regions of IVIV treated placebo and high dose animals (scale bar = 50 µm). ICIV and IVIV: Placebo: n = 22, Low dose: n = 20, Medium dose: n = 20, High dose: n = 17. IVIV: Placebo n = 12, High dose: n = 7. Data are mean ± s.e.m; *P < 0.05, ***P < 0.001; unpaired two-sided Mann–Whitney U test (d3 vs. d56) or Kruskal–Wallis test with Dunn’s multiple comparison (Placebo vs. treatment groups).
